Transparency Issues Floor Novo Nordisk's Tresiba At IQWiG
IQWiG has said that Novo Nordisk's refusal to make public part of its dossier for its diabetes therapy Tresiba represents a lack of transparency and makes the drug impossible to recommend.
IQWiG has said that Novo Nordisk's refusal to make public part of its dossier for its diabetes therapy Tresiba represents a lack of transparency and makes the drug impossible to recommend.